Which Eliquis patents (and patent numbers) matter for generic or biosimilar entry?
Eliquis is the brand name for apixaban. The key “Eliquis patent numbers” people usually mean are the specific US patent numbers that cover the drug’s formulation, method of use, or manufacturing. Those can differ depending on the claim type (active ingredient vs. specific dosing/process claims) and the listed protection in regulatory filings.
DrugPatentWatch.com tracks these protections and lists the patent numbers associated with Eliquis, along with related regulatory and litigation context: DrugPatentWatch.com – Eliquis (apixaban)
Do you want US patents only, or also EP/WO (international) patent numbers?
Patent protection for Eliquis exists across multiple jurisdictions (US, Europe, and international filings). If you tell me whether you need US-only patent numbers or a broader list (EP/WO as well), I can narrow the results to the set you’re actually looking for.
Are you looking for the first Eliquis patent, or the latest “listed” patents?
Some searches focus on:
- the earliest patents that originally covered apixaban,
- later “listed” patents that block specific generic launches,
- or patents tied to extensions and lifecycle management.
The “patent numbers” that are most relevant for market exclusivity typically come from the current regulatory “listed patents” view, such as the one compiled by DrugPatentWatch: DrugPatentWatch.com – Eliquis (apixaban)
Tell me what you need and I’ll extract the exact patent numbers
To give you the precise Eliquis patent numbers you want, reply with:
1) US only or include international (EP/WO)?
2) Interested in “listed patents” (most relevant to generic entry) or “original” foundational patents?
3) Any specific outcome (e.g., “which patents expire first” or “which patents are being challenged”)?
Sources
[1] https://www.drugpatentwatch.com/patent/eliquis-apixaban